electroCore, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28531P2020
USD
4.95
0.2 (4.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

38.06 k

Shareholding (Jun 2025)

FII

1.01%

Held by 9 FIIs

DII

94.29%

Held by 5 DIIs

Promoter

0.00%

How big is electroCore, Inc.?

22-Jun-2025

As of Jun 18, electroCore, Inc. has a market capitalization of 37.70 million, with net sales of 26.46 million and a net profit of -12.23 million over the latest four quarters. The company reported shareholder's funds of 7.54 million and total assets of 21.62 million as of Dec 24.

Market Cap: As of Jun 18, electroCore, Inc. has a market capitalization of 37.70 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, electroCore, Inc. reported net sales of 26.46 million and a net profit of -12.23 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 7.54 million and total assets of 21.62 million.

Read More

What does electroCore, Inc. do?

22-Jun-2025

ElectroCore, Inc. is a bioelectronic medicine company focused on developing non-invasive vagus nerve stimulation (nVNS) therapy for various medical conditions. As of March 2025, it reported net sales of $7 million and a net loss of $4 million, with a market capitalization of $37.70 million.

Overview:<BR>ElectroCore, Inc. is a commercial-stage bioelectronic medicine healthcare company engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for various medical conditions within the pharmaceuticals and biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 37.70 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.75 <BR>Return on Equity: -280.30% <BR>Price to Book: 8.64<BR><BR>Contact Details:<BR>Address: 150 Allen Rd Ste 201, Basking Ridge NJ: 07920-2977 <BR>Tel: 1 973 2900097 <BR>Fax: 1 973 2909171 <BR>Website: https://www.electrocore.com/

Read More

Should I buy, sell or hold electroCore, Inc.?

22-Jun-2025

Who are in the management team of electroCore, Inc.?

22-Jun-2025

As of March 2022, the management team of electroCore, Inc. includes Independent Chairman Mr. Michael Atieh, CEO and Director Mr. Daniel Goldberger, Directors Mr. Joseph Errico, Mr. Peter Cuneo, Dr. Thomas Errico, Mr. John Gandolfo, and Mr. Trevor Moody. They oversee the company's strategic direction and operations.

As of March 2022, the management team of electroCore, Inc. includes the following individuals:<BR><BR>- Mr. Michael Atieh, who serves as the Independent Chairman of the Board.<BR>- Mr. Daniel Goldberger, who is the Chief Executive Officer and a Director.<BR>- Mr. Joseph Errico, who is a Director.<BR>- Mr. Peter Cuneo, who is an Independent Director.<BR>- Dr. Thomas Errico, who is also an Independent Director.<BR>- Mr. John Gandolfo, who serves as an Independent Director.<BR>- Mr. Trevor Moody, who is an Independent Director.<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is electroCore, Inc. overvalued or undervalued?

20-Sep-2025

As of May 14, 2019, electroCore, Inc. is considered risky and overvalued due to a high Price to Book Value of 9.74, negative EV to EBIT and EV to EBITDA ratios, and a significantly negative Return on Equity of -280.30%, while its stock has underperformed the S&P 500 with a year-to-date return of -69.19%.

As of 14 May 2019, the valuation grade for electroCore, Inc. moved from does not qualify to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued, given its high Price to Book Value of 9.74 and negative EV to EBIT and EV to EBITDA ratios of -2.87 and -3.20, respectively. Additionally, the Return on Equity (ROE) is significantly negative at -280.30%, further supporting the overvaluation assessment.<BR><BR>In comparison to its peers, electroCore's P/E ratio is not applicable due to its loss-making status, while Delcath Systems, Inc. is considered expensive with a P/E of 68.06, and Neuronetics, Inc. has a risky valuation with an EV to EBITDA of -7.61. The stock has underperformed notably against the S&P 500, with a year-to-date return of -69.19% compared to the index's 12.22%, highlighting the challenges the company faces in the current market environment.

Read More

Is electroCore, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, electroCore, Inc. is in a bearish trend, indicated by negative signals from daily moving averages, monthly MACD, and Bollinger Bands, with a year-to-date return of -69.19% compared to the S&P 500's 12.22%.

As of 12 September 2025, the technical trend for electroCore, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including a bearish signal from the daily moving averages, a bearish monthly MACD, and a bearish monthly Bollinger Band. The weekly MACD shows a mildly bullish signal, but this is overshadowed by the overall bearish trend. Additionally, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -69.19% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky - Negative EBITDA

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -56.56%, its profits have risen by 25.1%
2

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 37 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-6.28

stock-summary
Return on Equity

-1,190.57%

stock-summary
Price to Book

33.52

Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.23%
0%
-3.23%
6 Months
-4.44%
0%
-4.44%
1 Year
-55.3%
0%
-55.3%
2 Years
-15.82%
0%
-15.82%
3 Years
-7.09%
0%
-7.09%
4 Years
-53.05%
0%
-53.05%
5 Years
-78.57%
0%
-78.57%

electroCore, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
57.70%
EBIT Growth (5y)
9.78%
EBIT to Interest (avg)
-18.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.75
Sales to Capital Employed (avg)
4.09
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.88%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.74
EV to EBIT
-2.87
EV to EBITDA
-3.20
EV to Capital Employed
-10.63
EV to Sales
1.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-280.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (4.7%)

Foreign Institutions

Held by 9 Foreign Institutions (1.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 21.31% vs 69.44% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -37.04% vs 44.90% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.40",
          "val2": "6.10",
          "chgp": "21.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.30",
          "val2": "-2.40",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-2.70",
          "chgp": "-37.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-475.00%",
          "val2": "-422.10%",
          "chgp": "-5.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 57.50% vs 86.05% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.70% vs 15.32% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.20",
          "val2": "16.00",
          "chgp": "57.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.90",
          "val2": "-17.50",
          "chgp": "37.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.90",
          "val2": "-18.80",
          "chgp": "36.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-483.00%",
          "val2": "-1,173.10%",
          "chgp": "69.01%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
7.40
6.10
21.31%
Operating Profit (PBDIT) excl Other Income
-3.30
-2.40
-37.50%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.70
-2.70
-37.04%
Operating Profit Margin (Excl OI)
-475.00%
-422.10%
-5.29%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 21.31% vs 69.44% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -37.04% vs 44.90% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
25.20
16.00
57.50%
Operating Profit (PBDIT) excl Other Income
-10.90
-17.50
37.71%
Interest
0.00
0.00
Exceptional Items
0.00
-0.50
100.00%
Consolidate Net Profit
-11.90
-18.80
36.70%
Operating Profit Margin (Excl OI)
-483.00%
-1,173.10%
69.01%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 57.50% vs 86.05% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.70% vs 15.32% in Dec 2023

stock-summaryCompany CV
About electroCore, Inc. stock-summary
stock-summary
electroCore, Inc.
Pharmaceuticals & Biotechnology
ElectroCore, Inc., formerly ElectroCore LLC, is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy, which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep and pain disorders.
Company Coordinates stock-summary
Company Details
150 Allen Rd Ste 201 , Basking Ridge NJ : 07920-2977
Registrar Details